INTRODUCTION
Liver malignancy represent the 6 th most common diagnosed cancer and 4 th most common death from cancer worldwide [1] . There are more than 700000 people diagnosed with primary liver malignancy annually and about 50% of the colorectal carcinoma patients may develop liver metastasis [2, 3] . Surgical resection or liver transplantation has been the preferred curative treatment for solid liver malignancy, unfortunately these treatments are only effective for early stage or localized liver tumors. The symptoms of liver cancer often appeared when cancer has progressed to the intermediate or advanced stage. In fact, more than 75% of the patients are diagnosed in intermediate or advanced stages where surgical resection or liver transplantation is no longer an option [4, 5] . The prognosis of unresectable liver cancer was poor in the past and the management of the disease was limited to systemic pharmacotherapy, external beam radiotherapy or palliative treatments [6] .
Radioembolization is an alternative minimally invasive treatment for intermediate and advanced stage liver cancer [7, 8] . The treatment takes advantage of differential blood supply for normal liver parenchyma and liver tumors. Liver tumors are usually rich in vasculature and receive blood almost exclusively from hepatic artery while the normal liver parenchyma cells receive blood predominately (about 80%) from the portal vein [9] [10] [11] . During the treatment, microspheres within the size of 20-60 µm labelled with a radionuclide that emits short range beta radiation are intraarterially administered. The microspheres are preferentially lodged near the terminal arterioles of the tumors and induces both radiation and embolization effects. Since the beta radiations only travel a few millimeters in the tissues, the healthy liver tissues and surrounding organs receive minimal radiation, while the tumors are exposed to a tumoricidal radiation dose [12] [13] [14] .
Currently, only the yttrium-90 ( 90 Y) microspheres approved by the United States Food and Drug Administration for the treatment of hepatocellular carcinoma and metastatic colorectal carcinoma. The 90 Y radioembolic agent are available in the forms of glass beads (TheraSphere ® , BTG Interventional Medicine, United Kingdom) and resin microspheres (SIR-Spheres ® , SIRTex Medical Limited, Australia) [15] . Nevertheless, there are several shortcomings that 90 Y microspheres need to overcome. The glass-and resin-based microspheres are biocompatible but not biodegradable, therefore the microspheres will remain in the liver permanently after administration. In addition, the density of the glass-based microsphere (3.6 g/mL) is approximately three times higher than the blood plasma (1.05 g/mL), hence it's settling velocity, injection and homogenous distribution of the glass microspheres within the tumor vascular are difficult to control [16] . 90 Y is a pure beta emitter and does not carry any imaging properties, evaluation of extrahepatic activity and liver dosimetry postadministration is often performed on 90 Y Bremsstrahlung single-photon emission computed tomography or positron emission tomography imaging that shows low quantitative accuracy or sensitivity [17] . Furthermore, 90 Y is commonly produced using a high-cost strontium-90 generator associated with complicated chemical separation process [18] .
Samarium-153 ( 153 Sm) is a potential radionuclide that can be used for hepatic radioembolization. 153 Sm can be produced from its non-radioactive isotope, 152 Sm via neutron activation, i.e., 152 Sm (n, γ) 153 Sm. The 153 Sm has been used for palliative pain treatment for bone metastases and radiosynovectomy in the past decades. The imaging properties of 153 Sm have been demonstrated in some previous studies of pharmacoscintigraphy and gastrointestinal imaging research [19] [20] [21] . The simultaneous emission of beta and gamma radiations from 153 Sm has rendered it a potential theranostic radionuclide for targeted cancer therapy.
This study aimed to develop a biodegradable radioembolic microspheres formulation loaded with 153 Sm to overcome the limitations of 90 Y microspheres for hepatic radioembolization. The physicochemical characteristics, radioactivity, radioimpurities as well as 153 Sm retention efficiency of the developed microspheres were studied and discussed in the following sections.
MATERIALS AND METHODS
Poly-L-lactic acid (PLLA) (viscosity = 0.8-1.2 dL/g), Samarium-152 acetylacetonate ( 152 SmAcAc) (99% purity) and polyvinyl alcohol (PVA, average molecular weight = 67000) were procured from Sigma Aldrich (St. Louis, MI, United States). Analytical grade chemicals and deionized water were used in all the experiments unless stated otherwise.
Preparation of 152 SmAcAc-PLLA microspheres
152 SmAcAc-PLLA microspheres with different concentrations of 152 SmAcAc were prepared using oil-in-water solvent evaporation method [22] . Firstly, 20 mL of chloroform solution containing 1.0 g of PLLA and different amounts of 152 SmAcAc (i.e., 1.0 g, 1.5 g, 1.75 g and 2.0 g) were added dropwise into 600 mL of 3% (w/v) PVA solution under overhead stirring at 950 rpm. The overhead stirring was continued for 12 h to allow evaporation of the chloroform. The resulting 152 SmAcAc-PLLA microspheres were then collected through vacuum filtration using a filter paper of 15 µm pores. Zero point one mol/L hydrochloride acid (HCl) and distilled water were used to dissolve and wash off any unbound 152 SmAcAc from the formulation. Subsequently, the microspheres were dried in a vacuum oven at room temperature for 48 h. Once the microspheres were completely dried, they were fractionated into 20-60 µm diameter using stainless steel sieves. Finally, the microspheres within 20-60 µm diameter were collected and stored in a sealed vial at -20 °C for further analysis.
Neutron activation of 152 SmAcAc-PLLA microspheres
The 152 SmAcAc-PLLA microspheres were sent for neutron activation using a 750 kW pool-type research reactor (TRIGA Mark II, General Atomics, CA, United States). Prior to neutron activation, the samples were transferred into a polyethylene vial and sealed. The samples were neutron-activated using either the pneumatic transfer system (PTS) or rotary specimen rack (RR) method. The neutron activation protocols for both PTS and RR methods are given in Table 1 . The radioactivity of the neutronactivated samples was measured using a calibrated dose calibrator (CRC 25R, Capintec, NJ, United States). The activity per microsphere was calculated by dividing the sample activity with the estimated number of microspheres present in the sample.
Physicochemical characterization of SmAcAc-PLLA microspheres before and after neutron activation
Physicochemical characterization of the SmAcAc-PLLA microspheres before and after neutron activation was carried out using scanning electron microscopy (SEM), energy dispersive X-ray (EDX) spectroscopy, particle size analyzer, Fourier transform infrared spectroscopy (FTIR), thermo-gravimetric analysis (TGA) and wavelength dispersive X-ray fluorescence (WDXRF) spectrometry. The objectives and methods of each test were elaborated in the following sections.
SEM and EDX spectroscopy:
Surface morphology of the SmAcAc-PLLA microspheres before and after neutron activation was examined using a SEM system (Quanta FEG 450, FEI, Oregon, United States). SEM images were obtained at 5 kV, 10 mm working distance and 2.0 spot size. Elemental compositions of the SmAcAc-PLLA microspheres before and after neutron activation were analyzed using EDX spectroscopy on the SEM system. The samples were mounted on aluminum stubs before performing the SEM and EDX analysis.
Laser scattering particle size analysis: The mean diameter and particle size distribution of the PLLA and SmAcAc-PLLA microspheres before and after neutron activation were determined using a laser scattering particle size distribution analyzer (Microtrac X100, Microtrac, United States). Microspheres samples suspended in distilled water were ultrasonicated before loading into the particle size analyzer for measurement.
FTIR spectroscopy: FTIR spectroscopy was performed to identify the chemical bonds of the microspheres. FTIR spectra within 600-4000 cm -1 of the PLLA, 152 SmAcAc and 152 SmAcAc-PLLA microspheres were obtained on a calibrated FTIR spectrometer (Spectrum 100, PerkinElmer Inc., MA, United States). Firstly, the samples were mixed with spectroscopy grade potassium bromide grain and dried in an oven to remove absorbed moisture. The potassium bromide-mixed samples were then pressed into pellets using designated tools provided by the manufacturer (PerkinElmer Inc., MA, United States) and subjected for FTIR analysis.
TGA: Thermal profiles of the 152 SmAcAc-PLLA microspheres were studied using a TGA 8000™ analyzer (PerkinElmer Inc., MA, United States). The profiles of its raw materials, PLLA and 152 SmAcAc, were also included for comparison. Approximately 5 mg of the sample was transferred into a ceramic sample pan and placed inside the TGA analyzer. The sample was then heated under nitrogen flow from 30-800 °C at a rate of 10 °C/min. TGA profiles of the samples were analyzed using the dedicated software (Pyris, PerkinElmer Inc., MA, United States).
WDXRF spectrometry:
The amount of 152 Sm presence in the 152 SmAcAc-PLLA microspheres with different 152 SmAcAc weight (1.0 g, 1.5 g, 1.75 g and 2.0 g) were determined using the semi-quantitative analysis of WDXRF spectrometry (Zetium, Malvern PANanalytical Ltd., Royston, United Kingdom).
Gamma spectroscopy
Gamma spectroscopy was performed at 24 h after neutron activation using a coaxial, p-type hyperpure germanium detector (Canberra, Meriden, United States) to identify the radionuclides present in the formulation. The sample was placed at a calibrated distance in the hyperpure germanium detector and counted for 5 min live time. The gamma spectrum was obtained and analyzed using dedicated software (Genie TM 2000 Ver. 3.2, Canberra, United States).
Density and viscosity measurements
The density of the 152 SmAcAc-PLLA microspheres were determined based on Archimedes principle. The density was calculated based on the relation given in Equation (1) . Mettler Toledo (ME 204) density meter (Ohio, United States) was used for this purpose.
(1) Density of Microspheres (ρ s ) = M b × ρ w / (M a -M w ) Where M b is the mass of the sample on a balance, M a is the mass of the sample in air, M w is the mass of the sample in water and is the density of water (1 g/cm 3 ). The ρ s was used to estimate the number of microspheres per gram of sample using Equation (2).
(2) Number of particles per gram = 6 × 10 12 / (π × ρ s × Dp 3 ) Where Dp is the mean diameter of the microspheres in µm and ρ s is the density of the microspheres in g/cm 3 .
The viscosity, η o of 153 SmAcAc-PLLA microspheres [2.5% (w/v)] suspended in sodium chloride (NaCl) solution was measured at 37 °C using a rheometer (HAAKE MARS, Thermo Fisher Scientific, MA, United States). The reading was then incorporated into the Stokes' Law to calculate the sedimentation rate (settling velocity) [13] .
(3) V sed = g × Dp 2 × (ρ s -ρ f ) / (18 × ηo) Where V sed is the sedimentation rate (cm/s), g is the gravitational acceleration constant (981 cm/s 2 ) and η o is the dynamic viscosity of the fluid (ρ f = g/cm/s).
In-vitro radiolabeling efficiency test
The radiolabeling efficiency of the neutron-activated 153 SmAcAc-PLLA microspheres was tested in both 0.9% NaCl solution and human blood plasma over a period of 550 h. The microspheres were suspended in the test solutions and continuously mixed at 50 rpm for 1 h using a roller mixer. The samples were then centrifuged at 2000 rpm for 10 min. One milliliter of the supernatant was then collected and assayed using an automated gamma counter (2470 Wizard 2 , PerkinElmer, MA, United States). The procedures were repeated until 8 mL of assay samples were collected over a period of 550 h [22] .
RESULTS

Synthesis of 152 SmAcAc-PLLA microspheres
The 152 SmAcAc-PLLA microspheres loaded with different amount of 152 SmAcAc (1.0 g, 1.5 g, 1.75 g and 2.0 g) were successfully synthesized using the solvent evaporation method. The synthesis parameters such as stirring rate (950 rpm), PVA concentration (3% w/v) and polymer solution concentration were optimized in this study in order to produce microspheres with a mean diameter of approximately 35 µm and size distribution within 20-60 µm.
Neutron activation
The 152 SmAcAc-PLLA microspheres were neutron-activated using two different methods: (1) Automatic PTS control where the samples were sent near to the reactor core and neutron-activated for a maximum duration of 5 min; and (2) Manual loading RR method where the samples were neutron-activated for an extended duration of 3 h and 6 h at the peripheral location from the reactor core. Table 1 shows the neutron activation protocols for both PTS and RR methods. The specific activity (GBq/g) achieved for different formulations and neutron activation methods are given in Figure 1 . The radioactivity increased linearly with the amount of 152 SmAcAc in the formulations. However, the maximum amount of 152 SmAcAc that can be loaded to the PLLA microsphere was 200% (w/w), and this achieved the maximum specific activity of 6.40 ± 0.07 GBq/g for a 6 h neutron activation using RR method. The radioactivity was proportional to the neutron activation time as theoretically known. Figure 2 shows the SEM images of the PLLA and SmAcAc-PLLA microspheres before and after neutron activation. Spherical microspheres were successfully produced following oil-in-water solvent evaporation synthesis. There is no 152 SmAcAc crystals were seen on the surface of the microspheres even at the highest concentration of 152 SmAcAc. In addition, the washing process using diluted HCl did not cause any physical damage to the microspheres. A prolonged neutron activation time of 6 h in the thermal neutron flux of 2.0 × 10 12 n/cm 2 /s 1 has produced physical damage and fragmentation on the microspheres. The damage and fragmentation were more severe at higher concentration of 152 SmAcAc. Nonetheless, neutron activation time of 3 h in the same neutron flux setting did not damage the physical structure of the microspheres. An extended part of the study has been carried out and found that neutron activation time longer than 4 h would cause physical damage and fragmentation of the PLLA microspheres (data were not included in this manuscript). Figure 3 shows the EDX spectrum of the PLLA microspheres and SmAcAc-PLLA microspheres before and after 3 h neutron activation. The spectra show the presence of carbon (C) and oxygen (O) in the PLLA microspheres, and C, O and Sm in the SmAcAc-PLLA microspheres. No other element was detected after neutron activation for both microspheres. The hydrogen (H) presence in the microspheres could not be detected by EDX due to the limitation of EDX in detecting any chemical element lower than atomic number of 6. In addition, no constituent of chloride from the diluted HCl washing was detected on the EDX spectrum of the SmAcAc-PLLA microspheres.
Physicochemical characterization of SmAcAc-PLLA microspheres before and after neutron activation
The mean diameter and size distribution of the PLLA and SmAcAc-PLLA microspheres before and after 3 h neutron activation are presented in Figure 4 . The mean diameter of the PLLA microspheres was 34.45 ± 0.20 µm and the size distribution was within 20 µm and 60 µm. Different concentrations of 152 SmAcAc in the PLLA microspheres did not change the size distribution significantly, however the mean diameter increased slightly with the amount of 152 SmAcAc loaded to the polymer. For instance, the mean diameter increased from 34.85 ± 0.17 µm to 38.25 ± 0.15 µm when the amount of 152 SmAcAc increased from 100% to 200% w/w. The mean diameter of the microspheres was not altered significantly after 3 h neutron activation. Figure 5 shows the FTIR spectrum of the PLLA (Figure 5A ), 152 SmAcAc-PLLA microspheres (Figure 5B -E) and 152 SmAcAc crystal ( Figure 5F ). The FTIR spectrum of the 152 SmAcAc crystal shows IR bands in the C=C and C=O regions (1700-1500 cm -1 ) ( Figure 5F ) [23] [24] [25] . The FTIR spectra of the 153 SmAcAc-PLLA microspheres indicated that the C= C vibration of acetylacetonate was noticed at 1515 cm -1 , similar to the wavelength for 152 SmAcAc crystals. On the other hand, the C= O region of the acetylacetonate was shifted from 1580 cm -1 in the 152 SmAcAc to 1610 cm -1 in the SmAcAc-PLLA microspheres ( Figure 5B-E) . This indicates that the PLLA carbonyl groups are interacting with the 152 SmAcAc complex, resulting in the immobilization of the 152 SmAcAc complex in the PLLA matrix. This in turn explains the low release characteristics of the 153 SmAcAc-PLLA microspheres. There was no band signal observed at these wavelengths in the FTIR spectrum of the PLLA microspheres ( Figure 5A ). In addition, there was no noticeable change in the C=O band of the PLLA (1760 cm -1 ) since any shift would be masked by the strong absorption band of the remaining, non-coordinating C=O bonds. Figure 6 shows the TGA profile of the PLLA, 152 SmAcAc-PLLA microspheres and 152 SmAcAc crystal. The PLLA microspheres showed only one event of mass loss, which can be ascribed to the decomposition of polymer main chain starting from 250°C
. The TGA profile of the 152 SmAcAc crystal shows multiple steps decomposition Table 2) . Figure 7 shows the gamma spectrum of the 153 SmAcAc-PLLA microspheres acquired at 24 h after neutron activation. Several photopeaks were observed at 41 keV, 47 keV, 69 keV and 103 keV on the gamma spectrum of the 153 SmAcAc-PLLA microspheres. The most dominant photopeak was found at 103 keV followed by a smaller photopeak at 69 keV. These energies corresponded to the principal gamma energies emitted by 153 Sm. The other two photopeaks (41 keV and 47 keV) were the K-shell characteristic X-rays emitted following internal conversion of 153 Sm. The gamma spectroscopy results were in accordance with the EDX spectroscopy results, showing no radionuclide impurities on the 152 SmAcAc-PLLA microspheres after neutron activation
Gamma spectroscopy
Density and viscosity measurement
The density of the 152 SmAcAc-PLLA microspheres ranged from 1.25 g/cm 3 to 1.35 g/cm 3 depending on the amount of the 152 SmAcAc added in the formulation ( Table 2 ).
The density values thus obtained were used to determine the number of microspheres per gram using Equation (2) given in the Methods section and the results are presented in 152 SmAcAc, respectively. The viscosity of the microspheres suspension at 2.5% (w/v) concentration at 37 °C are shown in Figure 8 . As demonstrated in the graph, the viscosity of the 152 SmAcAc-PLLA suspension at different shear rates were substantially similar and hence the average viscosity value was used to represent the viscosity of the respected microspheres suspension (Figure 8 ). The settling velocity (cm/s) of the formulation is depending on the viscosity, density and size of the microspheres. The settling velocity of 153 SmAcAc-PLLA are given in Table 2 .
In-vitro radiolabeling efficiency
The in-vitro radiolabeling of 153 SmAcAc-PLLA microspheres tested in 0.9% NaCl solution and human blood plasma is demonstrated in Figure 9 . The formulation showed excellent 153 Sm retention of more than 99% in 0.9% NaCl solution and human blood plasma over a test period of 550 h. A slightly lower 153 Sm retention efficiency was observed in human blood plasma than in the 0.9% NaCl solution but the difference was negligible (less than 1%).
DISCUSSION
Radioembolization with the use of radiolabelled microspheres has several advantages over external beam radiotherapy for hepatic malignancies. Firstly, it treats liver tumors by dual-mechanism pathways: Embolization (blocking blood supply to the liver tumors) and internal radiation therapy using high energy short-range radiations such as beta [26] . Secondly, it is useful to treat diffuse hepatocellular carcinoma or liver metastasis when surgery or local treatment is not possible. Thirdly, it minimizes radiation damage to the surrounding healthy tissues [27] . Current formulations approved by the United States Food and Drug Administration for radioembolization of liver metastasis are resin-based (SIR-Sphere) and glass-based (TheraSphere) microspheres labelled with pure beta emitter, 90 Y. Several researches have been conducted to explore alternative radionuclides and polymers to overcome some limitations of the 90 Y microspheres [28] [29] [30] [31] [32] . A theranostic radionuclide that emits both beta and gamma radiations is preferred to facilitate treatment planning and dosimetry. Compared to the generator-based radionuclide production, neutron activation is a preferred method due to its relatively lower cost of production, simpler process, wider availability of nuclear reactors globally and reduces international shipping of radioactive products. Examples of neutron-activated radionuclides include 166 Ho, 177 Lu, 186 Re and 188 Re. Biodegradable polymer is also favored in order to minimize the risk of long-term complications such as hepatitis and cirrhosis.
This study aimed to develop a biodegradable PLLA microspheres loaded with stable 152 SmAcAc. The microspheres were then activated using a nuclear reactor to produce radioactive 153 SmAcAc-PLLA microspheres that emits both beta (E β-max = 810 keV) and gamma (103 keV) radiations, potentially useful for theranostic radioembolization of liver malignancies. PLLA is biocompatible for human body and its degradation reaction is mainly due to hydrolysis to lactic acid. The lactic acid produced during the biodegradation of PLLA can serve as an energy substrate for cells and has been shown to have antioxidant properties [33] . In addition, the PLLA has a near blood plasma density and thus could overcome the high density drawback from glass-based 90 Y microspheres [28] . The developed 153 SmAcAc-loaded PLLA microspheres formulation combines the benefits of being biocompatible, biodegradable, similar density to human blood plasma, and emitting both therapeutic and diagnostic radiations (theranostic). Moreover, the production cost is reduced due to the relatively easier and cheaper neutron activation method.
A simple one-step oil-in-water solvent evaporation technique was used in this study to incorporate 152 SmAcAc crystals into the PLLA polymer. The 152 Sm was complexed with the acetylacetonate ligand to enable its incorporation into PLLA via oil-in-water solvent evaporation [34] . The 152 SmAcAc, ranging from 100 to 200% (w/w), was successfully encapsulated into the PLLA microspheres. Incorporation of 152 SmAcAc beyond 200% (w/w) has resulted in irregular shape of the microspheres with excessive unbound 152 SmAcAc crystals on the surface. The morphology and diameter of the microspheres were known to be affected by several synthesis parameters such as concentration of PVA and stirring rates, in which, a lower PVA concentration and stirring rate would produce microspheres with larger mean diameter and size distribution [35] . The optimum PVA concentration of 3% (w/w) and stirring rate of 950 rpm have resulted in spherical microspheres with a mean diameter of approximately 35 µm. The microspheres were sieved to obtain the size within 20-60 µm diameter, which is a strict requirement for intraarterial hepatic radioembolization [10] .
The integrity of the 153 SmAcAc-loaded PLLA microspheres after neutron activation is important to ensure its safe administration into human body. Several factors such as moisture content and neutron activation time are known to produce detrimental effects on the integrity of the PLLA microspheres [32] . In order to prevent deterioration during neutron activation, the formulations were dried in a vacuum oven for at least 48 h to remove any excessive moisture prior to neutron activation. The 153 SmAcAc-PLLA microspheres remained intact and spherical with similar size distribution after 3 h neutron activation but was fragmented when the neutron activation time was prolonged to 6 h. The formulation with a higher loading of 152 SmAcAc would experience a greater extent of fragmentation. The fragmentation maybe ascribed to the radiation damage to the PLLA microspheres. Similar fragmentation of PLLA microspheres after neutron activation has been observed in a previous study [32] . From the results of this study, the optimum neutron activation time for neutron activation of 152 SmAcAc-PLLA microspheres under a thermal neutron flux of 2 × 10 12 n/cm 2 /s 1 was determined as 3 h.
In order to facilitate intraarterial injection via a microcatheter, the radioembolic microspheres are usually suspended in 0.9% NaCl solution or distilled water. The 153 SmAcAc-PLLA microspheres suspension has a similar viscosity to the 0.9% NaCl solution (0.01 g/cm/s) but slightly lower than the viscosity of the human blood (0.03 g/cm/s) [36] . Owing to its lower density, the settling velocity of the 153 SmAcAc-PLLA microspheres suspension was relatively lower compared to the glass-and resin-based microspheres [28, 29, 37] . A lower settling velocity could prevent the microspheres from settling in the microcatheter or blood vessels during administration and enable a more homogenous distribution of the microspheres within the tumor volume. The retention efficiency of radioactive 153 Sm in the microspheres was excellent (> 99%) tested in both 0.9% NaCl solution and human blood plasma for an extended period of 550 h. High retention efficiency is required to minimize leakage of free 153 Sm to other parts of the body. The excellent retention efficiency of the formulation can be ascribed to the interaction between the carbonyl groups of PLLA with the 153 SmAcAc complex, which has resulted in the immobilization of the 153 SmAcAc complex in the PLLA matrix.
152 SmAcAc-PLLA microspheres with different concentrations of 152 SmAcAc, ranging from 100%-200% w/w, were tested in this study. Higher concentration of 152 SmAcAc is preferred to increase the specific activity of each microsphere. However, higher loading of 152 SmAcAc would increase the density and mean diameter of the microsphere. In addition, it also increased the difficulties in removing the unbound 152 SmAcAc. Therefore, it is important to find the optimum concentration of 152 SmAcAc to be loaded to each PLLA microsphere to achieve the desired properties for radioembolization of liver tumors. According to the results of this study, 175% (w/w) 152 SmAcAc is recommended as it produces microspheres with mean diameter of 37 µm and specific activity of 95 Bq per microsphere. This value is in between the protocols used in SIR-Sphere (40-70 Bq per microsphere) and TheraSphere (2500 Bq per microsphere). A further increase in the 152 SmAcAc concentration (e.g., from 175% to Although the specific activity (GBq/g) of the 153 SmAcAc-PLLA microspheres was slightly lower than the target therapeutic dose of 3.0 GBq per vial in 90 Y microspheres, administration of larger number of microspheres with medium specific activity has been suggested earlier [31] to produce better therapeutic efficacy than lower number of microspheres with higher specific activity. This is because a more even distribution of the radiation dose within the tumor volume is expected by a larger number of microspheres with lower specific activity while achieving the same total therapeutic dose prescribed for the treatment (total activity = number of microspheres x specific activity per microsphere). Nevertheless, a detailed dosimetry and treatment planning software are needed to determine the optimum dosage/approach for each individual patient. If necessary, the enriched form of 152 Sm (about 99% 152 Sm) can be used to replace the natural abundance 152 Sm (about 27% 152 Sm) if higher specific activity is desired. The radioactivity produced by the enriched 153 Sm is expected to be around three to four times higher than the natural abundant 153 Sm.
Production of radioactive formulations using neutron activation technique could possibly reduce the production cost and make the treatment more affordable across many nations. The commercially available 90 Y is produced from strontium-90, a fission product of uranium in a nuclear reactor, by chemical high-purity separation. The elution and radiolabeling process involves multiple steps involving advanced technology and skills. It also increases radiological burden to the personnel as the whole production process is done under radioactive environment [18] . In comparison, the preparation of 152 SmAcAc-PLLA microspheres is relatively easier, cheaper and does not involve ionizing radiation as non-radioactive form of 152 Sm is used during the synthesis process. The formulation can be kept and only sent for neutron activation when needed. According to the latest International Atomic Energy Agency Research Reactor Database, there are 224 research reactors currently operates across 53 countries [38] . If the formulation can be activated locally, it would significantly reduce cross-borders radioactive shipments and lead time hence more radioembolization patients can be benefited. Some studies have suggested using neutron-activated 188 Re and 166 Ho as a substitute to 90 Y, however these radionuclides have relatively short half-life, i.e., 17 h and 26 h, respectively. In our opinion, 153 Sm has an ideal half-life of 46.3 h and it emits both therapeutic beta energies and diagnostic range gamma radiation, renders it a useful theranostics agent for liver radioembolization. Furthermore, it is readily available in a stable chemical form ( 152 Sm, natural abundance 26%) and decays into a stable daughter ( 153 Eu), hence minimizing the risk of radioactive waste.
In conclusion, a biocompatible, biodegradable 152 SmAcAc-PLLA microspheres was successfully developed in this study. The microspheres have a mean diameter of approximately 37 µm and size distribution between 20 µm and 60 µm. The microspheres achieved a specific activity of 98 Bq per microsphere for the formulation loaded with 175% (w/w) 152 SmAcAc. No significant radionuclide impurities were found and the 153 Sm retention efficiency was above 99% when tested in 0.9% NaCl solution and human blood plasma for 550 h. Further studies are needed to complete the dosimetry and to compare the radioembolization efficiency with the commercially available formulations. 
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